Avalon Globocare Corp - Understand $albt stock

$ALBT Market Cap: $3.367 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.309M

TTM

Gross Margin

18.66%

TTM

Net Earnings

-$14.73M

TTM

Current Assets

$1.397M

Q3 2024

Current Liabilities

$12.33M

Q3 2024

Current Ratio

11.33%

Q3 2024

Total Assets

$19.55M

Q3 2024

Total Liabilities

$14.15M

Q3 2024

Book Value

$5.401M

Q3 2024

Cash

$1.024M

Q3 2024

P/E

-0.2285

Nov 12, 2024 EST

Free Cash Flow

-$1.713M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$1.256M	$1.202M	$1.391M	$1.380M	$1.550M	$1.560M	$1.080M	$620.0K	$0.00
YoY Change	4.45%	-13.57%	0.79%	-10.97%	-0.64%	44.44%	74.19%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	$1.256M	$1.202M	$1.391M	$1.380M	$1.550M	$1.560M	$1.080M	$620.0K	$0.00
Cost Of Revenue	$1.017M	$930.0K	$976.5K	$990.0K	$1.210M	$1.170M	$830.0K	$70.00K	$0.00
Gross Profit	$238.2K	$272.7K	$414.5K	$390.0K	$340.0K	$390.0K	$250.0K	$540.0K	$0.00
Gross Profit Margin	18.97%	22.69%	29.8%	28.26%	21.94%	25.0%	23.15%	87.1%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$7.310M	$6.980M	$6.828M	$11.89M	$16.89M	$8.000M	$2.800M	$470.0K	$100.0K
YoY Change	4.73%	2.22%	-42.57%	-29.6%	111.13%	185.71%	495.74%	370.0%
% of Gross Profit	3069.06%	2559.33%	1647.31%	3048.72%	4967.65%	2051.28%	1120.0%	87.04%
Research & Development	$109.6K	$731.3K	$900.0K	$810.0K	$1.750M
YoY Change	-85.01%	-18.74%	11.11%	-53.71%
% of Gross Profit	46.02%	268.15%	217.12%	207.69%	514.71%
Depreciation & Amortization	$211.7K	$330.7K	$311.8K	$310.0K	$510.0K	$520.0K	$180.0K	$0.00	$0.00
YoY Change	-35.98%	6.08%	0.57%	-39.22%	-1.92%	188.89%
% of Gross Profit	88.89%	121.26%	75.21%	79.49%	150.0%	133.33%	72.0%	0.0%
Operating Expenses	$7.420M	$9.066M	$900.0K	$12.84M	$18.70M	$8.020M	$2.810M	$470.0K	$100.0K
YoY Change	-18.15%	907.29%	-92.99%	-31.34%	133.17%	185.41%	497.87%	370.0%
Operating Profit	-$7.182M	-$8.793M	-$485.5K	-$12.45M	-$18.36M	-$7.630M	-$2.560M	$70.00K	-$100.0K
YoY Change	-18.32%	1711.18%	-96.1%	-32.19%	140.63%	198.05%	-3757.14%	-170.0%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Interest Expense	-$9.753M	$176.0K	-$260.9K	-$220.0K	$2.170M	-$470.0K	-$190.0K	$0.00	$0.00
YoY Change	-5641.45%	-167.45%	18.61%	-110.14%	-561.7%	147.37%
% of Operating Profit								0.0%
Other Income/Expense, Net	-$320.00	-$11.93M	$4.270K	$0.00	-$860.0K	$50.00K	$20.00K
YoY Change	-100.0%	-279510.94%		-100.0%	-1820.0%	150.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Pretax Income	-$16.71M	-$11.93M	-$9.091M	-$12.68M	-$17.31M	-$7.665M	-$3.795M	$80.00K	-$100.0K
YoY Change	40.03%	31.25%	-28.31%	-26.75%	125.83%	101.99%	-4843.59%	-180.0%
Income Tax	$0.00				$0.00	$0.00	$0.00	$20.00K	$0.00
% Of Pretax Income								25.0%
Net Earnings	-$16.71M	-$11.93M	-$9.091M	-$12.68M	-$18.07M	-$7.770M	-$3.460M	$60.00K	-$100.0K
YoY Change	40.03%	31.25%	-28.31%	-29.83%	132.56%	124.57%	-5866.67%	-160.0%
Net Earnings / Revenue	-1330.51%	-992.44%	-653.54%	-918.84%	-1165.81%	-498.08%	-320.37%	9.68%
Basic Earnings Per Share	-$1.59	-$1.28	-$1.07
Diluted Earnings Per Share	-$1.59	-$1.28	-$107.1K	-$159.5K	-$240.5K	-$107.9K	-$53.21K	$1.173K	-$2.000K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$285.4K	$1.990M	$807.5K	$730.0K	$760.0K	$2.250M	$3.030M	$2.890M	$110.0K
YoY Change	-85.66%	146.43%	10.62%	-3.95%	-66.22%	-25.74%	4.84%	2527.27%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$330.8K	$250.0K	$424.6K	$520.0K	$560.0K	$1.300M	$150.0K	$750.0K	$0.00
YoY Change	32.32%	-41.13%	-18.34%	-7.14%	-56.92%	766.67%	-80.0%
Inventory						$10.00K	$0.00
Prepaid Expenses
Receivables	$197.5K	$60.00K	$33.62K	$40.00K	$240.0K	$50.00K	$50.00K	$70.00K	$0.00
Other Receivables	$37.19K	$80.00K	$57.25K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$850.9K	$2.370M	$1.323M	$1.290M	$1.570M	$3.630M	$3.230M	$3.710M	$110.0K
YoY Change	-64.1%	79.13%	2.56%	-17.83%	-56.75%	12.38%	-12.94%	3272.73%
Property, Plant & Equipment	$7.358M	$7.510M	$8.036M	$8.300M	$8.340M	$8.130M	$7.670M	$0.00	$0.00
YoY Change	-2.03%	-6.54%	-3.19%	-0.48%	2.58%	6.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.10M	$9.480M	$515.6K	$520.0K	$480.0K	$390.0K
YoY Change	27.58%	1738.53%	-0.84%	8.33%	23.08%
Other Assets	$278.9K	$380.0K	$204.7K	$140.0K		$0.00	$180.0K
YoY Change	-26.6%	85.63%	46.22%			-100.0%
Total Long-Term Assets	$19.73M	$17.38M	$8.919M	$9.080M	$8.920M	$9.770M	$9.440M	$0.00	$0.00
YoY Change	13.53%	94.86%	-1.77%	1.79%	-8.7%	3.5%
Total Assets	$20.58M	$19.75M	$10.24M	$10.37M	$10.49M	$13.40M	$12.67M	$3.710M	$110.0K
YoY Change
Accounts Payable	$688.2K	$1.220M	$1.670M	$1.080M	$1.140M	$10.00K	$0.00	$10.00K	$20.00K
YoY Change	-43.59%	-26.95%	54.63%	-5.26%	11300.0%		-100.0%	-50.0%
Accrued Expenses	$2.972M	$2.360M	$2.340M	$1.440M	$1.620M	$810.0K	$220.0K	$10.00K	$20.00K
YoY Change	25.94%	0.86%	62.49%	-11.11%	100.0%	268.18%	2100.0%	-50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$1.925M	$0.00	$0.00	$0.00	$0.00	$0.00	$1.500M	$0.00	$0.00
YoY Change						-100.0%
Long-Term Debt Due			$390.0K
YoY Change
Total Short-Term Liabilities	$6.763M	$3.580M	$4.402M	$2.590M	$2.840M	$1.140M	$5.360M	$160.0K	$120.0K
YoY Change	88.9%	-18.67%	69.95%	-8.8%	149.12%	-78.73%	3250.0%	33.33%
Long-Term Debt	$6.446M	$4.560M	$2.750M	$3.590M	$3.190M	$1.000M	$0.00	$0.00	$0.00
YoY Change	41.36%	65.8%	-23.39%	12.54%	219.0%
Other Long-Term Liabilities	$4.860K	$450.0K	$5.900K	$70.00K
YoY Change	-98.92%	7527.12%	-91.57%
Total Long-Term Liabilities	$6.451M	$5.010M	$2.756M	$3.660M	$3.190M	$1.000M	$0.00	$0.00	$0.00
YoY Change	28.76%	81.77%	-24.7%	14.73%	219.0%
Total Liabilities	$13.21M	$8.590M	$7.158M	$6.250M	$6.030M	$1.280M	$4.770M	$160.0K	$120.0K
YoY Change	53.83%	20.01%	14.53%	3.65%	371.09%	-73.17%	2881.25%	33.33%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	10.53M shares	9.329M shares	8.491M shares
Diluted Shares Outstanding	10.53M shares	9.329M shares	8.491M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $3.3673 Million

About Avalon Globocare Corp

Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm offers diagnostic testing utilizing proprietary technology to deliver genetics-driven results. The company operates through two segments: Real property rental and Lab Services MSO. Lab Services MSO segment is focused on delivering services related to toxicology and wellness testing and provides a portfolio of diagnostic tests including drug testing, toxicology, and a range of test services, from general bloodwork to anatomic pathology, and urine toxicology. Its capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, and sexually transmitted disease testing. The Lab Services MSO segment is also focused on the commercialization of genetic-based proprietary testing. The company is also exploring the commercialization and development of a versatile breathalyzer system, KetoAir breathalyzer.

Industry: Biological Products, (No Diagnostic Substances) Peers: Capital Properties Inc Wave Sync Corp. DigitalBridge Group Inc LUXURBAN HOTELS INC. InterGroup Corp J W Mays Inc Rafael Holdings Inc Trinity Place Holdings Inc